about
Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelinesSeronegative antiphospholipid syndromeThe EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactationThe ANCA test: its clinical relevance.Moderate dose oral anticoagulant therapy in patients with the antiphospholipid syndrome? NoCharacteristics of patients with antiphospholipid syndrome with major bleeding after oral anticoagulant treatmentAntiaggregant and anticoagulant therapy in systemic lupus erythematosus and Hughes' syndromeAspirin to treat obstetric manifestations of the antiphospholipid syndromeAntiphospholipid antibodies do not a syndrome makeThe antiphospholipid antibody syndrome: diagnosis, skin manifestations and current therapyLongitudinal evaluation of markers of endothelial cell dysfunction and hemostasis in treated antiphospholipid syndrome and in healthy pregnancyTreatment of pregnancy loss in Hughes syndrome: a critical updateLongitudinal analysis of serum insulin-like growth factor-I and insulin-like growth factor binding protein-1 in antiphospholipid syndrome and in healthy pregnancyProphylaxis of the antiphospholipid syndrome: a consensus reportTreatment of pregnant patients with antiphospholipid syndromeSystematic lupus erythematosus and antiphospholipid syndrome during pregnancyAnti-inflammatory and immunosuppressive drugs and reproductionLow dose methotrexate treatment in adult Still's diseasePolymyositis complicating D-penicillamine treatmentFactors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception CohortClinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort.Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort.Google-driven search for big data in autoimmune geoepidemiology: analysis of 394,827 patients with systemic autoimmune diseases.Prevalence of an abnormal ankle-brachial index in patients with primary antiphospholipid syndrome: preliminary data.Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort.Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort.Antiferritin antibodies discovered by phage display expression cloning are associated with radiographic damage in rheumatoid arthritis.EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics.Antiphospholipid, anti-beta 2-glycoprotein-I and anti-oxidized-low-density-lipoprotein antibodies in antiphospholipid syndrome.Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus.Splenectomy for refractory thrombocytopenia in the antiphospholipid syndrome.A chimeric antibody with the human gamma1 constant region as a putative standard for assays to detect IgG beta2-glycoprotein I-dependent anticardiolipin and anti-beta2-glycoprotein I antibodies.The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5.Systemic lupus erythematosus in 50 year olds.Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients.Anticardiolipin antibodies in a patient with Crohn's disease and thrombosis.Features associated with epilepsy in the antiphospholipid syndrome.Reassessing the status of antiphospholipid syndrome in systemic lupus erythematosus.
P50
Q22255576-E941F5EF-9680-4036-8686-2A901827A2A9Q24674194-0C3906B3-F486-4638-AF13-DEBDFC4F728FQ26765038-E2112637-7A33-4D7A-B9E8-FAB9E34FC548Q27469297-B9640549-81FA-4039-A20B-BB02C2F250ECQ28174733-CC5B8264-997D-4C84-BC2E-8586F8F80DE8Q28181800-0F98AF8B-8F8D-4D81-B5DA-6633C692E42DQ28182136-D55F948C-0748-4EF7-868C-66BD6ABC63DFQ28188267-84C6CAB6-63F1-45A7-AD3C-F1203C4B253CQ28192812-FCA4E560-3D81-4FA8-A943-58EB9385AC00Q28194927-59708457-0A9E-445A-AFF6-D5F77DDC8DB3Q28194971-D73AA6DA-3D3E-4179-AD69-2F6551E3E7F0Q28196667-5C7A24A6-8A39-43BC-86E6-CA4DA57B2F7AQ28196730-9811BB6E-07E9-4647-8115-4A905A1AF4D2Q28196923-CD0E523B-A45D-4FE4-8F36-BA20BC9B4FC2Q28196925-019520E8-F0E6-4039-83EF-45485A322F79Q28217439-BA59CD03-7094-41EF-A3F5-1B8E0F4844B6Q28218219-92DD7BDA-A61E-44D4-9E71-DDE7EA1B6045Q28319741-CF54B01E-58DC-4F04-9EC6-BDBC295AC6DCQ28325364-CEB0BAF6-FEB9-427E-A687-A09A1194BCC7Q28608340-9DAF1BB0-A5C3-4CA9-A3E9-8E24A66C1A84Q30560952-4F66A5DA-EFE9-45A8-9899-CC1CEA81F7CEQ30791606-EB5689DE-9CCF-4FA3-8816-3A40889631C1Q30923489-4BD58757-2248-4B93-9C57-2DFB81A6643CQ30978841-AFAF20F6-1B06-411F-8185-A318B5A17C32Q31122937-7145233E-878E-4706-8FC6-2B4B34FE0DDFQ31145074-07D7C02A-D2E7-4972-AC4F-1F2DB98AA6A4Q33228254-8CCAD582-9142-4AE4-9EEA-CE0957A4D331Q33284736-1204C832-0710-4412-B41F-D1C6947E44C7Q33327909-9D0E0833-D945-4CAE-8135-EAD28CE6C2EAQ33329033-63EA1AB6-67B8-4E96-B79F-C7F81DF6239CQ33330250-2F66E254-053E-4189-AAC8-9C5DC089BED7Q33330540-05F52C59-7D52-4B98-AF8B-407F8279FFB6Q33340382-72EA0B5F-8A15-442F-BC32-F87B013F0CFFQ33341941-85EA4FFB-E83D-4FB2-8A9B-1DBC6139636DQ33342481-D3FC94D8-CB91-4CC4-A008-BDA75839C99EQ33356370-59876623-073F-4D40-832A-71BD54A6D1D3Q33357081-C4DE5C05-A037-49C8-B201-D71468F00706Q33360177-E5CE0B20-89D0-4BCC-8902-3F3A9CF7A9CBQ33361525-81D0A70A-E2B3-41B7-B084-AF5C0B26AF92Q33363443-0597E220-7F21-45A2-801A-1482E8AA2BE4
P50
description
forsker
@nb
researcher
@en
ricercatore
@it
name
Munther A. Khamashta
@da
Munther A. Khamashta
@de
Munther A. Khamashta
@en
Munther A. Khamashta
@fr
Munther A. Khamashta
@nb
Munther A. Khamashta
@nl
Munther A. Khamashta
@nn
Munther A. Khamashta
@sv
type
label
Munther A. Khamashta
@da
Munther A. Khamashta
@de
Munther A. Khamashta
@en
Munther A. Khamashta
@fr
Munther A. Khamashta
@nb
Munther A. Khamashta
@nl
Munther A. Khamashta
@nn
Munther A. Khamashta
@sv
altLabel
Munther A Khamashta
@en
Munther Khamashta
@en
prefLabel
Munther A. Khamashta
@da
Munther A. Khamashta
@de
Munther A. Khamashta
@en
Munther A. Khamashta
@fr
Munther A. Khamashta
@nb
Munther A. Khamashta
@nl
Munther A. Khamashta
@nn
Munther A. Khamashta
@sv
P1006
P214
P1006
P106
P1580
P21
P214
P31
P569
1957-01-01T00:00:00Z
P7859
lccn-n93802888